Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support
HFNC may leads to lower treatment failure (escalation of respiratory therapy to NIV, NIPPV… compared with standard oxygen therapy (low certainty).
1 finding from 1 review
Adverse events ‐ pneumonia · adults in the ICU, requiring respiratory support
It is very uncertain whether HFNC changes adverse events Respiratory infection (pneumonia) compared with NIPPV or NIV (very low certainty).
1 finding from 1 review
Barotrauma (pneumothorax) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in barotrauma (pneumothorax) compared with NIPPV or NIV (low certainty).
1 finding from 1 review
Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · adults in the ICU, requiring respiratory support
1 finding from 1 review
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Adverse events Respiratory infection (pneumonia) Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in adverse events Respiratory infection (pneumonia) Nasal mucosa or… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Duration of ICU stay · adults in the ICU, requiring respiratory support
1 finding from 1 review
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in treatment failure (escalation of respiratory therapy to NIV, NIPPV… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (selenium) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Length of hospital stay · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review